| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Ray Dalio | Bridgewater Associates | $12M | 0.1% | 2026-06-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Methodology breakdown computing — it will appear here on its own.
Royalty Pharma plc - Ordinary Shares - Class A (RPRX) is currently considered not halal (non-compliant), per our secondary compliance provider (last assessed 2026-08-12). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computing the full ratio and business-activity breakdown for RPRX — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 42.50 | NEUTRAL |
| Stochastic %K (14) | 2.09 | BUY |
| CCI (20) | -93.98 | NEUTRAL |
| Williams %R (14) | -97.91 | BUY |
| MACD (12,26,9) | -0.37 | SELL |
| ROC (10) | -4.93 | SELL |
| Momentum (10) | -3.05 | SELL |
| EMA (10) | 61.22 | SELL |
| SMA (10) | 61.74 | SELL |
| EMA (20) | 60.85 | SELL |
| SMA (20) | 61.11 | SELL |
| EMA (30) | 60.24 | SELL |
| SMA (30) | 59.96 | SELL |
| EMA (50) | 58.98 | SELL |
| SMA (50) | 59.01 | SELL |
| EMA (100) | 55.83 | BUY |
| SMA (100) | 55.83 | BUY |
| EMA (200) | 49.73 | BUY |
| SMA (200) | 49.20 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Background via Yahoo Finance — informational, not part of the verdict.
No real edge — avoid
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | RANGING | 43 |
| ⏰ 4H | RANGING | 39 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.
